{"id":765046,"date":"2023-06-21T08:23:24","date_gmt":"2023-06-21T12:23:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-of-ne3017-in-alzheimers-disease-data-at-83rd-scientific-sessions-of-the-american-diabetes-association\/"},"modified":"2023-06-21T08:23:24","modified_gmt":"2023-06-21T12:23:24","slug":"biovie-to-present-of-ne3017-in-alzheimers-disease-data-at-83rd-scientific-sessions-of-the-american-diabetes-association","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-of-ne3017-in-alzheimers-disease-data-at-83rd-scientific-sessions-of-the-american-diabetes-association\/","title":{"rendered":"BioVie To Present of NE3017 in Alzheimer\u2019s Disease Data at 83rd Scientific Sessions of the American Diabetes Association"},"content":{"rendered":"
\n

CARSON CITY, Nev., June 21, 2023 (GLOBE NEWSWIRE) — BioVie Inc., (NASDAQ: BIVI) (\u201cBioVie\u201d or the \u201cCompany\u201d) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders\u00a0and advanced liver disease,\u00a0today announced that an abstract highlighting baseline data from its multicenter, randomized, placebo-controlled Phase 3 study (NCT04669028<\/a>) of NE3107 in patients with mild to moderate Alzheimer\u2019s disease will be presented as a poster at the 83rd<\/sup> Scientific Sessions of the American Diabetes Association, to be held June 23-26, 2023 in San Diego, CA.<\/p>\n

The poster, Metabolic Dysregulation in Probable Alzheimer\u2019s Disease <\/em>(Christopher Reading, et al), discusses the role of insulin resistance and neuroinflammation in the risk of mild cognitive impairment and Alzheimer\u2019s Disease, and details baseline metabolic and inflammation characteristics from the Phase 3 study, including data on the regulation of glycemia. <\/p>\n

\n Presentation Details<\/strong>\n <\/p>\n

\n Title<\/strong>: Metabolic Dysregulation in Probable Alzheimer\u2019s Disease<\/em>
Poster<\/strong>: #1520
Category<\/strong>: 21-C Insulin Action\u2014Signaling and Insulin Resistance
Date\/Time<\/strong>: Saturday Jun 24, 2023 11:30 AM – 12:30 PM<\/p>\n

\n About BioVie\u00a0<\/strong>\u00a0<\/p>\n

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company\u2019s drug candidate NE3107 inhibits inflammatory activation of ERK and NFkB (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of Alzheimer\u2019s and Parkinson\u2019s diseases. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer’s disease (NCT04669028). Results of a Phase 2 investigator initiated trial (NCT05227820) showing NE3107-treated patients experienced improved cognition and biomarker levels were presented at the Clinical Trial in Alzheimer\u2019s Disease (CTAD) annual conference in December 2022. An estimated six million Americans suffer from Alzheimer\u2019s. A Phase 2 study of NE3107 in Parkinson\u2019s disease (NCT05083260) has completed, and data presented at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Disorders conference in Gothenburg, Sweden in March 2023 showed significant improvements in \u201cmorning on\u201d symptoms and clinically meaningful improvement in motor control in patients treated with a combination of NE3107 and levodopa vs. patients treated with levodopa alone, and no drug-related adverse events. In liver disease, the Company\u2019s Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated in a US Phase 2b study for the treatment of refractory ascites due to liver cirrhosis. BIV201 is administered as a patent-pending liquid formulation. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit http:\/\/www.bioviepharma.com\/<\/u><\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>\u00a0<\/p>\n

\n This press release contains forward-looking statements, including statements regarding the Company\u2019s strategy, plans and objectives, such as statements regarding the Company\u2019s anticipated timeline for announcing results from the NE3107 Phase 3 potential pivotal trials.\u202fForward-looking statements may generally be identified by words such as “expect,” “look forward to,” “anticipate” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “project” or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due risks associated with conducting and completing clinical trials, including our reliance on third parties to conduct our clinical trials, to successfully defend potential future litigation, our ability to raise capital when needed on reasonable terms, changes in local or national economic conditions\u202fas well as various additional risks, many of which are now unknown and generally out of the Company’s control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.\u202f <\/em>\n <\/p>\n

\n
\n For Investor Relations Inquiries:<\/em>
\n <\/strong>\u00a0<\/p>\n\n\n\n\n\n\n
Contact:\u00a0\u00a0<\/td>\n<\/tr>\n
\n Bruce Mackle\u00a0<\/strong>\n <\/td>\n<\/tr>\n
\n Managing Director<\/em>\u00a0<\/td>\n<\/tr>\n
\n LifeSci Advisors, LLC<\/strong>\u00a0\u00a0<\/td>\n<\/tr>\n
\n bmackle@lifesciadvisors.com<\/a>\u00a0<\/td>\n<\/tr>\n<\/table>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

CARSON CITY, Nev., June 21, 2023 (GLOBE NEWSWIRE) — BioVie Inc., (NASDAQ: BIVI) (\u201cBioVie\u201d or the \u201cCompany\u201d) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders\u00a0and advanced liver disease,\u00a0today announced that an abstract highlighting baseline data from its multicenter, randomized, placebo-controlled Phase 3 study (NCT04669028) of NE3107 in patients with mild to moderate Alzheimer\u2019s disease will be presented as a poster at the 83rd Scientific Sessions of the American Diabetes Association, to be held June 23-26, 2023 in San Diego, CA. The poster, Metabolic Dysregulation in Probable Alzheimer\u2019s Disease (Christopher Reading, et al), discusses the role of insulin resistance and neuroinflammation in the risk of mild cognitive impairment and Alzheimer\u2019s Disease, and details baseline … <\/p>\n

Continue reading “BioVie To Present of NE3017 in Alzheimer\u2019s Disease Data at 83rd Scientific Sessions of the American Diabetes Association”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-765046","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBioVie To Present of NE3017 in Alzheimer\u2019s Disease Data at 83rd Scientific Sessions of the American Diabetes Association - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-of-ne3017-in-alzheimers-disease-data-at-83rd-scientific-sessions-of-the-american-diabetes-association\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioVie To Present of NE3017 in Alzheimer\u2019s Disease Data at 83rd Scientific Sessions of the American Diabetes Association - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CARSON CITY, Nev., June 21, 2023 (GLOBE NEWSWIRE) — BioVie Inc., (NASDAQ: BIVI) (\u201cBioVie\u201d or the \u201cCompany\u201d) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders\u00a0and advanced liver disease,\u00a0today announced that an abstract highlighting baseline data from its multicenter, randomized, placebo-controlled Phase 3 study (NCT04669028) of NE3107 in patients with mild to moderate Alzheimer\u2019s disease will be presented as a poster at the 83rd Scientific Sessions of the American Diabetes Association, to be held June 23-26, 2023 in San Diego, CA. The poster, Metabolic Dysregulation in Probable Alzheimer\u2019s Disease (Christopher Reading, et al), discusses the role of insulin resistance and neuroinflammation in the risk of mild cognitive impairment and Alzheimer\u2019s Disease, and details baseline … Continue reading "BioVie To Present of NE3017 in Alzheimer\u2019s Disease Data at 83rd Scientific Sessions of the American Diabetes Association"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-of-ne3017-in-alzheimers-disease-data-at-83rd-scientific-sessions-of-the-american-diabetes-association\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-21T12:23:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MTUxMCM1NjU2MjI4IzUwMDA3OTY2Ng==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-to-present-of-ne3017-in-alzheimers-disease-data-at-83rd-scientific-sessions-of-the-american-diabetes-association\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-to-present-of-ne3017-in-alzheimers-disease-data-at-83rd-scientific-sessions-of-the-american-diabetes-association\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BioVie To Present of NE3017 in Alzheimer\u2019s Disease Data at 83rd Scientific Sessions of the American Diabetes Association\",\"datePublished\":\"2023-06-21T12:23:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-to-present-of-ne3017-in-alzheimers-disease-data-at-83rd-scientific-sessions-of-the-american-diabetes-association\\\/\"},\"wordCount\":702,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-to-present-of-ne3017-in-alzheimers-disease-data-at-83rd-scientific-sessions-of-the-american-diabetes-association\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MTUxMCM1NjU2MjI4IzUwMDA3OTY2Ng==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-to-present-of-ne3017-in-alzheimers-disease-data-at-83rd-scientific-sessions-of-the-american-diabetes-association\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-to-present-of-ne3017-in-alzheimers-disease-data-at-83rd-scientific-sessions-of-the-american-diabetes-association\\\/\",\"name\":\"BioVie To Present of NE3017 in Alzheimer\u2019s Disease Data at 83rd Scientific Sessions of the American Diabetes Association - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-to-present-of-ne3017-in-alzheimers-disease-data-at-83rd-scientific-sessions-of-the-american-diabetes-association\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-to-present-of-ne3017-in-alzheimers-disease-data-at-83rd-scientific-sessions-of-the-american-diabetes-association\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MTUxMCM1NjU2MjI4IzUwMDA3OTY2Ng==\",\"datePublished\":\"2023-06-21T12:23:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-to-present-of-ne3017-in-alzheimers-disease-data-at-83rd-scientific-sessions-of-the-american-diabetes-association\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-to-present-of-ne3017-in-alzheimers-disease-data-at-83rd-scientific-sessions-of-the-american-diabetes-association\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-to-present-of-ne3017-in-alzheimers-disease-data-at-83rd-scientific-sessions-of-the-american-diabetes-association\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MTUxMCM1NjU2MjI4IzUwMDA3OTY2Ng==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MTUxMCM1NjU2MjI4IzUwMDA3OTY2Ng==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-to-present-of-ne3017-in-alzheimers-disease-data-at-83rd-scientific-sessions-of-the-american-diabetes-association\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioVie To Present of NE3017 in Alzheimer\u2019s Disease Data at 83rd Scientific Sessions of the American Diabetes Association\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioVie To Present of NE3017 in Alzheimer\u2019s Disease Data at 83rd Scientific Sessions of the American Diabetes Association - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-of-ne3017-in-alzheimers-disease-data-at-83rd-scientific-sessions-of-the-american-diabetes-association\/","og_locale":"en_US","og_type":"article","og_title":"BioVie To Present of NE3017 in Alzheimer\u2019s Disease Data at 83rd Scientific Sessions of the American Diabetes Association - Market Newsdesk","og_description":"CARSON CITY, Nev., June 21, 2023 (GLOBE NEWSWIRE) — BioVie Inc., (NASDAQ: BIVI) (\u201cBioVie\u201d or the \u201cCompany\u201d) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders\u00a0and advanced liver disease,\u00a0today announced that an abstract highlighting baseline data from its multicenter, randomized, placebo-controlled Phase 3 study (NCT04669028) of NE3107 in patients with mild to moderate Alzheimer\u2019s disease will be presented as a poster at the 83rd Scientific Sessions of the American Diabetes Association, to be held June 23-26, 2023 in San Diego, CA. The poster, Metabolic Dysregulation in Probable Alzheimer\u2019s Disease (Christopher Reading, et al), discusses the role of insulin resistance and neuroinflammation in the risk of mild cognitive impairment and Alzheimer\u2019s Disease, and details baseline … Continue reading \"BioVie To Present of NE3017 in Alzheimer\u2019s Disease Data at 83rd Scientific Sessions of the American Diabetes Association\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-of-ne3017-in-alzheimers-disease-data-at-83rd-scientific-sessions-of-the-american-diabetes-association\/","og_site_name":"Market Newsdesk","article_published_time":"2023-06-21T12:23:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MTUxMCM1NjU2MjI4IzUwMDA3OTY2Ng==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-of-ne3017-in-alzheimers-disease-data-at-83rd-scientific-sessions-of-the-american-diabetes-association\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-of-ne3017-in-alzheimers-disease-data-at-83rd-scientific-sessions-of-the-american-diabetes-association\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BioVie To Present of NE3017 in Alzheimer\u2019s Disease Data at 83rd Scientific Sessions of the American Diabetes Association","datePublished":"2023-06-21T12:23:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-of-ne3017-in-alzheimers-disease-data-at-83rd-scientific-sessions-of-the-american-diabetes-association\/"},"wordCount":702,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-of-ne3017-in-alzheimers-disease-data-at-83rd-scientific-sessions-of-the-american-diabetes-association\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MTUxMCM1NjU2MjI4IzUwMDA3OTY2Ng==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-of-ne3017-in-alzheimers-disease-data-at-83rd-scientific-sessions-of-the-american-diabetes-association\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-of-ne3017-in-alzheimers-disease-data-at-83rd-scientific-sessions-of-the-american-diabetes-association\/","name":"BioVie To Present of NE3017 in Alzheimer\u2019s Disease Data at 83rd Scientific Sessions of the American Diabetes Association - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-of-ne3017-in-alzheimers-disease-data-at-83rd-scientific-sessions-of-the-american-diabetes-association\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-of-ne3017-in-alzheimers-disease-data-at-83rd-scientific-sessions-of-the-american-diabetes-association\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MTUxMCM1NjU2MjI4IzUwMDA3OTY2Ng==","datePublished":"2023-06-21T12:23:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-of-ne3017-in-alzheimers-disease-data-at-83rd-scientific-sessions-of-the-american-diabetes-association\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-of-ne3017-in-alzheimers-disease-data-at-83rd-scientific-sessions-of-the-american-diabetes-association\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-of-ne3017-in-alzheimers-disease-data-at-83rd-scientific-sessions-of-the-american-diabetes-association\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MTUxMCM1NjU2MjI4IzUwMDA3OTY2Ng==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MTUxMCM1NjU2MjI4IzUwMDA3OTY2Ng=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-of-ne3017-in-alzheimers-disease-data-at-83rd-scientific-sessions-of-the-american-diabetes-association\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BioVie To Present of NE3017 in Alzheimer\u2019s Disease Data at 83rd Scientific Sessions of the American Diabetes Association"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/765046","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=765046"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/765046\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=765046"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=765046"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=765046"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}